Health tech investors outline investment priorities in AI
06 Mar 2024
(This story is from our new Health Tech newsletter. If you’d like to sign up,
just click here
.)
Venture capital, private and non-profit investors who spoke at a panel in New York this week laid out their investment priorities in health tech companies that use AI, saying they’re interested in how artificial intelligence can improve behavioral health and drug development.
Andreessen Horowitz investment partner Daisy Wolf told the audience of a panel at Cornell Tech’s HealthNext Summit on Tuesday that she believes AI is going to drive drug discovery and health diagnosis so that people can have a doctor in their pockets. AI can also save clinicians time and boost efficiency by getting rid of frustrating minutiae in healthcare, she added.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.